MARKET

XERS

XERS

Xeris Pharmaceuticals
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.170
0.000
0.00%
After Hours: 2.290 +0.12 +5.53% 17:48 05/23 EDT
OPEN
2.220
PREV CLOSE
2.170
HIGH
2.225
LOW
2.140
VOLUME
718.92K
TURNOVER
0
52 WEEK HIGH
4.980
52 WEEK LOW
1.250
MARKET CAP
294.10M
P/E (TTM)
-1.4743
1D
5D
1M
3M
1Y
5Y
73 Biggest Movers From Yesterday
Gainers AgriFORCE Growing Systems Ltd. (NASDAQ: AGRI) shares jumped 65.9% to close at $2.77 on Monday after gaining around 10% on Friday.
Benzinga · 6d ago
Xeris Biopharma spikes as CEO buys company shares
Micro-cap pharma stock Xeris Biopharma (NASDAQ:XERS) has added more than a quarter of value to record its biggest ever intraday gain on Monday after the Chief Executive Paul R. Edick
Seekingalpha · 05/16 18:37
XERS, AGRX and LHDX among mid-day movers
Gainers: Data Storage Corporation (DTST) +40%. Indonesia Energy Corporation (INDO) +30%. Harpoon Therapeutics (HARP) +28%. Pulse Biosciences (PLSE) +24%. Praxis Precision Medicines (PRAX) +24%. Xeris Biopharma Holdings (XERS) +24%. Griffon
Seekingalpha · 05/16 16:31
Xeris Announces Full Results From The Logics Study Of Recorlev And Presentation Of New Burden Of Illness In Cushing's Syndrome Data At AACE Annual Meeting May 12-14
Xeris Announces Full Results From the Logics Study of Recorlev® and Presentation of New Burden of Illness in Cushing's Syndrome Data at AACE Annual Meeting May 12-14 Xeris Biopharma Holdings, Inc. (NASDAQ:XERS),
Benzinga · 05/12 20:18
Xeris Announces Full Results From the Logics Study of Recorlev® and Presentation of New Burden of Illness in Cushing’s Syndrome Data at AACE Annual Meeting May 12-14
CHICAGO, May 12, 2022--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, today announced it is presenting ne...
Business Wire · 05/12 20:02
Xeris stock falls after missing Q1 revenue estimates
Xeris Pharma (NASDAQ:XERS -8.1%) stock fell after the company posted lower-than-expected Q1 net product revenue. Net Product Revenue rose 172% Y/Y to $21.91M, but missed analysts estimates by $1.48M. Net Loss
Seekingalpha · 05/11 15:19
The Daily Biotech Pulse: Veru Shares Up On COVID Candidate Update, FDA Approves Lilly's COVID Treatment, Latest On Sanofi-AstraZeneca RSV Vaccine
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · 05/11 13:37
Xeris Biopharma Holdings: Q1 Earnings Insights
  Xeris Biopharma Holdings (NASDAQ:XERS) reported its Q1 earnings results on Wednesday, May 11, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Benzinga · 05/11 11:46
More
No Data
Learn about the latest financial forecast of XERS. Analyze the recent business situations of Xeris Pharmaceuticals through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

33.33%Strong Buy
66.67%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average XERS stock price target is 6.25 with a high estimate of 7.00 and a low estimate of 6.00.
High7.00
Average6.25
Low6.00
Current 2.170
EPS
Actual
Estimate
-0.40-0.37-0.35-0.32
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Institutional Holdings
Institutions: 140
Institutional Holdings: 54.61M
% Owned: 40.29%
Shares Outstanding: 135.53M
TypeInstitutionsShares
Increased
32
6.38M
New
26
8.29M
Decreased
26
4.42M
Sold Out
14
799.40K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.48%
Pharmaceuticals & Medical Research
+0.70%
Key Executives
Chairman/Chief Executive Officer/Director
Paul Edick
President/Chief Operating Officer/Director
John Shannon
Co-Founder/Chief Scientific Officer
Steven Prestrelski
Chief Financial Officer/Director
Steven Pieper
Senior Vice President/General Counsel/Secretary/Director
Beth Hecht
Senior Vice President
Kenneth Johnson
No Data
No Data
About XERS
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The Company has two products, Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia and Keveyis, a therapy for primary periodic paralysis. The Company uses its non-aqueous formulation technology platforms, XeriSol and XeriJect, to develop and commercialize its products. The XeriSol formulation technology is suited for peptides and small molecules that encounter formulation challenges. The XeriJect formulation technology is suited for drugs and biologics consisting of large molecules such as proteins, monoclonal antibodies, and vaccines.

Webull offers kinds of Xeris Biopharma Holdings Inc stock information, including NASDAQ:XERS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XERS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading XERS stock methods without spending real money on the virtual paper trading platform.